Related Experiment Video

Updated: Aug 1, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.0K

Are we getting closer to offering deep brain stimulation for treatment-resistant depression in clinical practice?

Liming Qiu1, Casey H Halpern1,2, Daniel A N Barbosa3

  • 1Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Molecular Psychiatry
|April 27, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.4K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.3K

Related Experiment Videos

Last Updated: Aug 1, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.0K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.4K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.3K

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

93
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
93

Articles linked to this work by shared authors, journal, and citation graph.

Shared Spectral Parameters Between EEG and Basal Ganglia LFP Distinguish Sleep-Specific Oscillations in Parkinson's Disease.

European journal of neurology·2026

Cross-species brain-wide mapping reveals convergent mesocorticolimbic engagement by nucleus accumbens deep brain stimulation.

Molecular psychiatry·2026

Microscale organization and separability of upper extremity representations in the human motor homunculus.

Research square·2026

Electrographic cue-reactivity co-localizes with accumbens deep brain stimulation in a case of opioid use disorder.

Nature communications·2026

Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.

Nature medicine·2025

Stereo-encephalography-guided multi-lead deep brain stimulation for treatment-refractory obsessive compulsive disorder - study design and individualized surgical targeting approach.

medRxiv : the preprint server for health sciences·2025

TNF-dependent regulation of synaptic plasticity and neuronal activity: implications for psychiatric disorders.

Molecular psychiatry·2026

Pharmacological and non-pharmacological modulation of striatal dopamine release: a meta-analysis of [11C]raclopride PET studies.

Molecular psychiatry·2026

YTHDF1 modulates CAP1-mediated actin turnover to regulate synaptic function and anxiodepressive-like behaviors.

Molecular psychiatry·2026

Severe PTSD symptoms magnify episodic memory-encoding deficits and amygdala-ACC attenuation during unpredictable threat in male combat veterans.

Molecular psychiatry·2026

Developmental and cellular vulnerabilities underlie genetic architecture of schizophrenia.

Molecular psychiatry·2026

Advanced glycation end products drive blood-brain barrier lipid dysregulation via RAGE-ABCA1 signaling to promote neurovascular dysfunction in Alzheimer's disease.

Molecular psychiatry·2026

Radiocopper in BCMA-targeted immunotheranostics of myeloma.

Theranostics·2026

hNET-targeted [18F]MFBG PET as baseline functional imaging in newly diagnosed neuroblastoma.

Theranostics·2026

Nano-flow intracalvariosseous infusion enables skull-to-brain delivery of BBB-impermeable molecular and nanoscale agents in mice and rabbits.

Theranostics·2026

Design of a Pragmatic Randomized Controlled Trial for Comparing the Michigan Screening and Intervention for Glaucoma and Eye Health and Telemedicine Protocol with Usual Care for Disease Detection.

Clinical ophthalmology (Auckland, N.Z.)·2026

Erratum: Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy: Erratum.

Theranostics·2026

Correction: Editorial: Advancements in meningioma management: from imaging techniques to personalized medicine approaches.

Frontiers in neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us